Saturday, July 11, 2026

Drug profile · INN

tolmetin sodium

tolmetin sodium (TOLECTIN DS) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tolmetin sodium
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

tolmetin sodium (TOLECTIN DS) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN tolmetin sodium
Brand TOLECTIN DS
Mechanism Cyclooxygenase inhibitor
Target Cyclooxygenase
Route ORAL
Formulation CAPSULE

Mechanism of action

Cyclooxygenase inhibitor

Primary target: Cyclooxygenase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aspirin Cyclooxygenase inhibitor
  2. bromfenac sodium Cyclooxygenase inhibitor
  3. diclofenac potassium Cyclooxygenase inhibitor
  4. diclofenac sodium Cyclooxygenase inhibitor
  5. diflunisal Nervous system (N02)
  6. fenoprofen calcium Cyclooxygenase inhibitor

Frequently asked questions

What is tolmetin sodium?

tolmetin sodium (TOLECTIN DS) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for tolmetin sodium?

TOLECTIN DS is a marketed brand name for tolmetin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tolmetin sodium?

tolmetin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.